


#3

EXPRESS MAIL MAILING LABEL	
NUMBER	EL 522 496 735 US
DATE OF DEPOSIT	November 30, 2001
I hereby certify that this paper or fee is being deposited with the United States Postal Service with sufficient postage "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: U.S. Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202	
 Pam Mitchell	

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Philip E. Thorpe and Sophia Ran

Prior Serial No.: 09/351,543
Prior Filing Date: July 12, 1999

Serial No.: Unknown

Filing Date: November 30, 2001

For: COMBINED CANCER TREATMENT
METHODS USING ANTIBODIES TO
AMINOPHOSPHOLIPIDS

Group Art Unit: 1642

Examiner: Bansal, G.

Atty. Dkt. No.: 4001.002299

PRE AT AMENDMENT
P#3
2-12-02

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination on the merits, the Examiner is respectfully requested to enter the following amendments. Remarks supporting patentability of all claims are also included, which the Examiner is respectfully requested to consider. All claims are believed to be condition for allowance, and examination and consideration is respectfully requested on this basis.

AMENDMENT

In the Specification:

In the title, please delete the existing title and replace this with a replacement title that reads:

COMBINED CANCER TREATMENT METHODS USING ANTIBODIES TO AMINOPHOSPHOLIPIDS

At page 1, after the heading 'Background of the Invention', please delete the existing paragraph or section of the Application pertaining to "Cross-reference to Related Applications" and replace such deleted paragraph or section with the following replacement paragraph or section:

The present application is a continuation of co-pending U.S. patent application Serial No. 09/351,543, filed July 12, 1999, which claims priority to first provisional application Serial No. 60/092,672, filed July 13, 1998, and second provisional application Serial No. 60/110,608, filed December 02, 1998, the entire text and figures of which applications are incorporated herein by reference without disclaimer. The U.S. Government owns rights in the present invention pursuant to grant numbers 1RO1CA74951-01 and 5RO1CA54168-05 from the National Institutes of Health.

In the Claims:

Upon filing the present continuation, please cancel claims 1-3, 11-22, 28-40 and 42-48 without prejudice and without disclaimer.

Please amend claims 4-10, 23 and 25, so that the rewritten claims read as follows:

4. (Amended) A method for treating an animal having a vascularized tumor, comprising simultaneously or sequentially administering to said animal a therapeutically effective

combination of at least a first pharmaceutical composition comprising at least a first antibody, or antigen-binding fragment thereof, that binds to an aminophospholipid on the luminal surface of blood vessels of the vascularized tumor and at least a second therapeutic agent; wherein said second therapeutic agent is:

- (a) a chemotherapeutic agent selected from the chemotherapeutic agents listed in Table B;
- (b) an anti-angiogenic agent selected from the anti-angiogenic agents listed in Table C;
- (c) an inflammatory cytokine, H_2O_2 or thrombin;
- (d) a compound that interferes with tubulin activity; or
- (e) a calcium flux inducing agent.

5. (Amended) The method of claim 4, wherein said at least a first antibody, or antigen-binding fragment thereof, binds to phosphatidylethanolamine on the luminal surface of blood vessels of the vascularized tumor.

6. (Amended) The method of claim 4, wherein said at least a first antibody, or antigen-binding fragment thereof, binds to phosphatidylserine on the luminal surface of blood vessels of the vascularized tumor.

7. (Amended) The method of claim 4, wherein said at least a first antibody is an IgG or IgM anti-aminophospholipid antibody.

8. (Amended) The method of claim 4, wherein said at least a first antigen-binding fragment of an antibody is an scFv, Fv, Fab', Fab or F(ab')₂ antigen-binding fragment of an anti-aminophospholipid antibody.

9. (Amended) The method of claim 4, wherein said at least a first antibody is a human, humanized or part-human chimeric anti-aminophospholipid antibody or antigen-binding fragment thereof.

10. (Amended) The method of claim 4, wherein said at least a first antibody is an anti-aminophospholipid monoclonal antibody or antigen-binding fragment thereof.

23. (Amended) The method of claim 4, wherein said at least a first antibody is a dimer, trimer or multimer of an anti-aminophospholipid antibody or antigen-binding fragments thereof.

25. (Amended) The method of claim 4, wherein said at least a first pharmaceutical composition is administered to said animal via intravenous administration.

Upon filing the present continuation, please add claims 49-68, as follows:

49. (New) The method of claim 4, wherein said at least a second therapeutic agent is a chemotherapeutic agent selected from the chemotherapeutic agents listed in Table B.

50. (New) The method of claim 49, wherein said at least a second therapeutic agent is cytosine arabinoside, methotrexate, aminopterin, demecolcine, mithramycin, chlorambucil,

melphalan, daunorubicin, doxorubicin, verapamil, tamoxifen, taxol, vincristine, vinblastine, etoposide, 5-fluorouracil (5FU), camptothecin, actinomycin-D, mitomycin C, cisplatin, a combretastatin or cyclophosphamide.

51. (New) The method of claim 4, wherein said at least a second therapeutic agent is an anti-angiogenic agent selected from the anti-angiogenic agents listed in Table C.

52. (New) The method of claim 51, wherein said at least a second therapeutic agent is angiostatin or endostatin.

53. (New) The method of claim 4, wherein said at least a second therapeutic agent is an inflammatory cytokine.

54. (New) The method of claim 53, wherein said at least a second therapeutic agent is interleukin-4.

55. (New) The method of claim 4, wherein said at least a second therapeutic agent is H₂O₂.

56. (New) The method of claim 4, wherein said at least a second therapeutic agent is thrombin.

57. (New) The method of claim 4, wherein said at least a second therapeutic agent is a compound that interferes with tubulin activity.

58. (New) The method of claim 57, wherein said at least a second therapeutic agent is taxol, vincristine, vinblastine, bleomycin, or a combretastatin.

59. (New) The method of claim 4, wherein said at least a second therapeutic agent is a calcium-flux inducing agent.

60. (Ncw) The method of claim 60, wherein said at least a second therapeutic agent is a calcium ionophore.

61. (Ncw) The method of claim 4, wherein said at least a first antibody and said at least a second therapeutic agent are administered to said animal simultaneously.

62. (New) The method of claim 4, wherein said at least a first antibody and said at least a second therapeutic agent are administered to said animal sequentially.

63. (New) The method of claim 62, wherein said at least a second therapeutic agent is administered to said animal at a biologically effective time prior to said at least a first antibody.

64. (New) The method of claim 63, wherein said at least a second therapeutic agent injures or induces apoptosis in the endothelium of the blood vessels of said vascularized tumor.

65. (New) The method of claim 64, wherein said at least a second therapeutic agent is taxol, vincristine, vinblastine, neomycin, a combretastatin, a podophyllotoxin, TNF- α , angiostatin, endostatin, vasculostatin, an $\alpha_v\beta_3$ antagonist, a calcium ionophore or a calcium-flux inducing agent; or is a prodrug thereof.

66. (New) The method of claim 62, wherein said at least a second therapeutic agent is administered to said animal at a biologically effective time subsequent to said at least a first antibody.

67. (New) The method of claim 66, wherein said at least a second therapeutic agent is an anti-tumor cell immunotoxin or an anti-angiogenic agent.

68. (New) A method for treating cancer, comprising simultaneously or sequentially administering to an animal having a vascularized tumor a therapeutically effective combination of an unconjugated antibody that binds to an aminophospholipid on the luminal surface of blood vessels of the vascularized tumor and at least a second therapeutic agent.

REMARKS

I. Continuing Application Status

The present application is a continuation of allowed, co-pending application Serial No. 09/351,543, filed July 12, 1999 ("the '543 application"; Attorney Docket No. 4001.002200). The inventorship remains the same as the earlier application.

The '543 application was filed with claims 1-48, directed to therapeutic methods that comprise administering to an animal an effective amount of at least a first naked (unconjugated)

antibody, or antigen-binding region thereof, that binds to an aminophospholipid on the luminal surface of tumor vascular endothelial cells. All claims were examined without entry of a restriction or species election requirement. The original and certain new claims were progressed to allowance, and a copy of the allowed claims is enclosed (**Exhibit D**). Within the claims allowed, certain claims recited the simultaneous or sequential administration of a second anti-cancer agent along with the anti-aminophospholipid naked antibody.

This continuation is directed to further combined treatment methods, which complement those allowed in the parent application by reciting certain particular therapeutic agents for joint administration. The present claims are largely based on claims 4, 28 and 47 as allowed in the '543 application, but revised to reflect certain exemplary species of therapeutic agent from the specification.

Applicants respectfully request that the preceding amendments to the specification and claims be entered prior to substantive examination of this application. All of the amendments and additionally presented claims are fully supported by the original parent, and earlier priority application, to which priority is still properly claimed.

II. Status of the Claims

On filing the present continuation, claims 1-3, 11-22, 28-40 and 42-48 from the parent application have been cancelled without prejudice or disclaimer. Claims 4-10, 23 and 25 have been amended, to reflect the invention of the continuation. Claims 49-68 have been added, which are unified with the amended claims and fully supported by the original specification. Claims 4-10, 23-27, 41 and 49-68 are therefore in the case.

III. Compliance with 37 C.F.R. § 1.121

Copies of the pending claims are attached hereto as **Exhibit A** and **Exhibit B**. In accordance with 37 C.F.R. § 1.121, the claims have been labeled as "(Amended)" or "(New)", where appropriate. **Exhibit A** provides a clean copy of the pending claims, whereas **Exhibit B** shows the changes with brackets and underlining.

The title of the present application has been changed to better reflect the claims. The proper claim for priority has been timely introduced into the specification by amendment of the opening paragraph at page 1.

The amendments to the title, specification and claims comply with 37 C.F.R. § 1.121, as the required instructions, text in clean form, and separate copies marked to show the changes using brackets and underlining are all submitted (see **Exhibit C** for specification, and **Exhibit B** for claims).

IV. The Claims are Allowable

The claims allowed in the parent application include dependent (claim 28) and independent (claim 47) claims directed to the simultaneous or sequential administration of at least a second anti-cancer agent in combination with the claimed naked antibody (**Exhibit D**). The second agents recited in the claims are chemotherapeutic, radiotherapeutic, anti-angiogenic and apoptosis-inducing agents (claims 29 and 48) and anti-tumor immunoconjugates (claims 30-40 and 48). Although several examples of anti-tumor immunoconjugates are recited in claims 30-40, the claims do not specify any particular examples of chemotherapeutic, radiotherapeutic or anti-angiogenic agents.

The present continuation is directed to combination treatment methods reciting particular examples of second therapeutic agents, as supported by the original specification. The pending

claims are thus directed to species of combined treatment methods that were disclosed, but not claimed in the parent application.

Although not necessary to support the claims, Applicants also provide **Exhibit E** for the record, which is a manuscript describing certain studies relevant to the present invention, submitted for publication on behalf of the inventors. **Exhibit E** includes data showing that various factors and tumor-associated conditions known to be present in the tumor microenvironment are able to cause PS translocation in cultured endothelial cells. Hypoxia/reoxygenation, acidity, thrombin, and inflammatory cytokines, such as IL-1 α , IL-1 β , TNF α and IFN, are all shown to induce PS exposure without causing cytotoxicity. Hydrogen peroxide is also shown to be a strong inducer of PS.

From the data in **Exhibit E**, the inventors propose that conditions inside tumors generate reactive oxygen species that could induce PS exposure. It is explained that the agents or conditions shown to induce PS are associated with a rise of intracellular Ca²⁺ concentration, which could cause PS accumulation on the external side of the membrane by activating the scramblase enzyme and/or by inhibiting aminophospholipid translocase. Moreover, combined treatment with inflammatory cytokines and hypoxia-reoxygenation are shown to have greater than additive effects, suggesting that factors may interact to give amplified effects on PS-exposure on tumor endothelium *in vivo*.

Irrespective of the data in **Exhibit E**, and the mechanistic discussions therein, the allowance of all claims in the parent application, and particularly the allowance of claims directed to combination treatment methods in general, supports a finding of patentability for the present claims, which recite further examples of combination treatment described in the specification. Given that all requirements of patentability have been addressed in the parent

application, the present claims should also be free from rejection. Applicants therefore urge that the claims be immediately progressed to allowance.

Should a Terminal Disclaimer be deemed necessary to secure allowance of the claims, a telephone call to the Applicants' undersigned representative is solicited in order that the Disclaimer can be supplied without delay.

V. Additional Support for the Claims

As described above, the present claims are directed to combination treatment methods using particular species of therapeutic agents within the scope of the sub-generic methods allowed in the parent application. Support for combination treatment clearly exists in claims 28 and 47 of the parent application, as well as throughout the specification, particularly in the extensive section of the specification entitled "Combination Therapies" (Section J, at pages 118-146). Other than as described below, the direct relationship between the pending claims and those of the parent application is evidenced in **Exhibit B** and **Exhibit D**. Additional support for the present claims in the specification exists as follows.

In claim 4, the term "simultaneously or sequentially" administering a therapeutically effective "combination" has direct support in original claim 47. The "at least a second therapeutic agent" is supported by allowed claims 28 and 47, as supplemented by the specification at least at page 19, line 17, page 107, line 25 and at page 118, lines 18-30.

In definitions (a) and (b) of claim 4, the therapeutic agents are defined as a chemotherapeutic agent selected from Table B and an anti-angiogenic agent selected from Table C, as supported by Tables B and C, beginning at pages 124 and 128 of the specification, respectively.

In claim 4(c), the therapeutic agent is defined as an inflammatory cytokine, H₂O₂ or thrombin. Inflammatory cytokines are described in the specification at page 121, lines 16-23, as supplemented by page 40, line 18 and in Example XIII. The use of H₂O₂ and thrombin is detailed in Example XIII, at pages 173-176 in particular.

Claim 4(d) recites that the therapeutic agent is a compound that interferes with tubulin activity, as supported by the specification at least at page 122, lines 23-24.

In claim 4(e), the therapeutic agent is defined as a calcium flux inducing agent, as recited in the specification at least at page 33, line 11 and at page 120, line 7.

The revisions to claims 5-10, 23 and 25 are clerical and/or grammatical, and are supported by the claims themselves.

Various of the new dependent claims simply recite alternatives (a) through (e) of claim 4 separate from the other alternatives, as follows: claim 49, 4(a); claim 51, 4(b); claims 53, 55 and 56, each 4(c); claim 57, 4(d); and claim 59, 4(e). The intervening claims then recite particular examples of certain agents, as below.

Claim 50 recites certain examples of chemotherapeutic agents from Table B and Section J1, and as supplemented by those recited at page 33, lines 9-11, at page 122, lines 10-26, and in the text bridging pages 139 and 140.

Claim 52 specifies the anti-angiogenic agent as angiostatin or endostatin, as described in the specification at pages 128, 130 and 131.

Claim 54 exemplifies the inflammatory cytokine as interleukin-4, as listed in the specification at page 40, line 18 and at page 121, line 18.

Claim 58 recites exemplary therapeutic agents known to interfere with tubulin activity, as taxol, vincristine, vinblastine, bleomycin, or a combretastatin, as described at page 122, second and fourth paragraphs, and as supplemented by page 125, fourth line from bottom.

Claim 60 exemplifies the calcium-flux inducing agent with reference to a calcium ionophore, as recited in the specification at page 33, line 11.

Dependent claims 61 and 62 separately recite the simultaneous and sequential administration from claim 4 (see also, pages 119-120).

Within sequential administration, the "prior" administration of the second agent, as recited in claims 63, 64 and 65, is described by the specification at least at page 33, lines 5-12, page 119, lines 12-14 and at page 120, lines 5-9.

The "subsequent" administration of the second agent, as recited in claims 66 and 67, is described by the specification at least from page 32, line 27 to page 33, line 3, and at page 120, lines 9-11.

Finally, independent claim 68 is similar to claim 4, but recites only the use of the intact antibody, to the exclusion of the antigen-binding fragment thereof, as supported by allowed claims 54 and 61 in the parent application and by original claims 4, 47 and 7.

The foregoing support confirms that no new matter is included within any of the pending claims.

VI. Formalities

Formal drawings are enclosed herewith. The sequence requirements and Applicants' initial duty of disclosure are also met (see paragraphs in the Request for Continuation and enclosed Statement and courtesy copies of sequence listing and 1449s).

No fees should be due in addition to the enclosed filing fees. However, should any additional fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason, the Assistant Commissioner is authorized to deduct said fees from Williams, Morgan & Amerson, P.C. Deposit Account No. 50-0786/4001.002299.

VII. Conclusion

In conclusion, Applicants submit that, in light of the foregoing remarks, the present claims are in condition for allowance and an early indication to this effect is respectfully requested. Should Examiner Bansal have any questions or comments, a telephone call to the undersigned Applicants' representative is earnestly solicited.

Respectfully submitted,



Shelley P.M. Fussey
Reg. No. 39,458
Agent for Applicants

WILLIAMS, MORGAN & AMERSON, P.C.
7676 Hillmont, Suite 250
Houston, Texas, 77040
(713) 934-4079

Date: November 30, 2001

EXHIBIT A
PENDING CLAIMS (4001.002299)

4. (Amended) A method for treating an animal having a vascularized tumor, comprising simultaneously or sequentially administering to said animal a therapeutically effective combination of at least a first pharmaceutical composition comprising at least a first antibody, or antigen-binding fragment thereof, that binds to an aminophospholipid on the luminal surface of blood vessels of the vascularized tumor and at least a second therapeutic agent; wherein said second therapeutic agent is:

- (a) a chemotherapeutic agent selected from the chemotherapeutic agents listed in Table B;
- (b) an anti-angiogenic agent selected from the anti-angiogenic agents listed in Table C;
- (c) an inflammatory cytokine, H_2O_2 or thrombin;
- (d) a compound that interferes with tubulin activity; or
- (e) a calcium flux inducing agent.

5. (Amended) The method of claim 4, wherein said at least a first antibody, or antigen-binding fragment thereof, binds to phosphatidylethanolamine on the luminal surface of blood vessels of the vascularized tumor.

6. (Amended) The method of claim 4, wherein said at least a first antibody, or antigen-binding fragment thereof, binds to phosphatidylserine on the luminal surface of blood vessels of the vascularized tumor.

7. (Amended) The method of claim 4, wherein said at least a first antibody is an IgG or IgM anti-aminophospholipid antibody.

8. (Amended) The method of claim 4, wherein said at least a first antigen-binding fragment of an antibody is an scFv, Fv, Fab', Fab or F(ab')₂ antigen-binding fragment of an anti-aminophospholipid antibody.

9. (Amended) The method of claim 4, wherein said at least a first antibody is a human, humanized or part-human chimeric anti-aminophospholipid antibody or antigen-binding fragment thereof.
10. (Amended) The method of claim 4, wherein said at least a first antibody is an anti-aminophospholipid monoclonal antibody or antigen-binding fragment thereof.
23. (Amended) The method of claim 4, wherein said at least a first antibody is a dimer, trimer or multimer of an anti-aminophospholipid antibody or antigen-binding fragments thereof.
24. The method of claim 4, wherein at least a second antibody that binds to an aminophospholipid, or an antigen-binding fragment thereof, is administered to said animal.
25. (Amended) The method of claim 4, wherein said at least a first pharmaceutical composition is administered to said animal via intravenous administration.
26. The method of claim 4, wherein an image of the vasculature of said vascularized tumor is first obtained by administering to said animal a diagnostically effective amount of a detectably-labeled antibody, or antigen-binding fragment thereof, that binds to and identifies an aminophospholipid on the luminal surface of blood vessels of the vascularized tumor.
27. The method of claim 4, further comprising subjecting said animal to surgery or radiotherapy.
41. The method of claim 4, wherein said animal is a human patient.
49. (New) The method of claim 4, wherein said at least a second therapeutic agent is a chemotherapeutic agent selected from the chemotherapeutic agents listed in Table B.
50. (New) The method of claim 49, wherein said at least a second therapeutic agent is cytosine arabinoside, methotrexate, aminopterin, demecolcine, mithramycin, chlorambucil, melphalan, daunorubicin, doxorubicin, verapamil, tamoxifen, taxol, vincristine, vinblastine, etoposide, 5-fluorouracil (5FU), camptothecin, actinomycin-D, mitomycin C, cisplatin, a combretastatin or cyclophosphamide.

51. (New) The method of claim 4, wherein said at least a second therapeutic agent is an anti-angiogenic agent selected from the anti-angiogenic agents listed in Table C.

52. (New) The method of claim 51, wherein said at least a second therapeutic agent is angiostatin or endostatin.

53. (New) The method of claim 4, wherein said at least a second therapeutic agent is an inflammatory cytokine.

54. (New) The method of claim 53, wherein said at least a second therapeutic agent is interleukin-4.

55. (New) The method of claim 4, wherein said at least a second therapeutic agent is H₂O₂.

56. (New) The method of claim 4, wherein said at least a second therapeutic agent is thrombin.

57. (New) The method of claim 4, wherein said at least a second therapeutic agent is a compound that interferes with tubulin activity.

58. (New) The method of claim 57, wherein said at least a second therapeutic agent is taxol, vincristine, vinblastine, bleomycin, or a combretastatin.

59. (New) The method of claim 4, wherein said at least a second therapeutic agent is a calcium-flux inducing agent.

60. (New) The method of claim 4, wherein said at least a second therapeutic agent is a calcium ionophore.

61. (New) The method of claim 4, wherein said at least a first antibody and said at least a second therapeutic agent are administered to said animal simultaneously.

62. (New) The method of claim 4, wherein said at least a first antibody and said at least a second therapeutic agent are administered to said animal sequentially.

63. (New) The method of claim 62, wherein said at least a second therapeutic agent is administered to said animal at a biologically effective time prior to said at least a first antibody.

64. (New) The method of claim 63, wherein said at least a second therapeutic agent injures or induces apoptosis in the endothelium of the blood vessels of said vascularized tumor.

65. (New) The method of claim 64, wherein said at least a second therapeutic agent is taxol, vincristine, vinblastine, neomycin, a combretastatin, a podophyllotoxin, TNF- α , angiostatin, endostatin, vasculostatin, an $\alpha_v\beta_3$ antagonist, a calcium ionophore or a calcium-flux inducing agent; or is a prodrug thereof.

66. (New) The method of claim 62, wherein said at least a second therapeutic agent is administered to said animal at a biologically effective time subsequent to said at least a first antibody.

67. (New) The method of claim 66, wherein said at least a second therapeutic agent is an anti-tumor cell immunotoxin or an anti-angiogenic agent.

68. (New) A method for treating cancer, comprising simultaneously or sequentially administering to an animal having a vascularized tumor a therapeutically effective combination of an unconjugated antibody that binds to an aminophospholipid on the luminal surface of blood vessels of the vascularized tumor and at least a second therapeutic agent.

EXHIBIT B
PENDING CLAIMS (4001.002299)

Cancel claims 1-3

4. (Amended) A method for treating an animal having a vascularized tumor, comprising simultaneously or sequentially administering to said animal a therapeutically effective [amount] combination of at least a first pharmaceutical composition comprising at least a first antibody, or antigen-binding fragment thereof, that binds to an aminophospholipid on the luminal surface of blood vessels of the vascularized tumor and at least a second therapeutic agent; wherein said second therapeutic agent is:

- (a) a chemotherapeutic agent selected from the chemotherapeutic agents listed in Table B;
- (b) an anti-angiogenic agent selected from the anti-angiogenic agents listed in Table C;
- (c) an inflammatory cytokine, H₂O₂ or thrombin;
- (d) a compound that interferes with tubulin activity; or
- (c) a calcium flux inducing agent.

5. (Amended) The method of claim 4, wherein said [pharmaceutical composition comprises] at least a first antibody, or antigen-binding fragment thereof, [that] binds to phosphatidylethanolamine on the luminal surface of blood vessels of the vascularized tumor.

6. (Amended) The method of claim 4, wherein said [pharmaceutical composition comprises] at least a first antibody, or antigen-binding fragment thereof, [that] binds to phosphatidylserine on the luminal surface of blood vessels of the vascularized tumor.

7. (Amended) The method of claim 4, wherein said [pharmaceutical composition comprises] at least a first antibody is an IgG or IgM anti-aminophospholipid antibody.

8. (Amended) The method of claim 4, wherein said [pharmaceutical composition comprises] at least a first antigen-binding fragment of an antibody is an scFv, Fv, Fab', Fab or F(ab')₂ antigen-binding fragment of an anti-aminophospholipid antibody.

9. (Amended) The method of claim 4, wherein said [pharmaceutical composition comprises] at least a first antibody is a human, humanized or part-human chimeric anti-aminophospholipid antibody or antigen-binding fragment thereof.

10. (Amended) The method of claim 4, wherein said [pharmaceutical composition comprises] at least a first antibody is an anti-aminophospholipid monoclonal antibody or antigen-binding fragment thereof.

Cancel claims 11-22

23. (Amended) The method of claim 4, wherein said [pharmaceutical composition comprises] at least a first antibody is a dimer, trimer or multimer of an anti-aminophospholipid antibody or antigen-binding fragments thereof.

24. The method of claim 4, wherein at least a second antibody that binds to an aminophospholipid, or an antigen-binding fragment thereof, is administered to said animal.

25. (Amended) The method of claim 4, wherein said at least a first pharmaceutical composition is administered to said animal via intravenous administration.

26. The method of claim 4, wherein an image of the vasculature of said vascularized tumor is first obtained by administering to said animal a diagnostically effective amount of a detectably-labeled antibody, or antigen-binding fragment thereof, that binds to and identifies an aminophospholipid on the luminal surface of blood vessels of the vascularized tumor.

27. The method of claim 4, further comprising subjecting said animal to surgery or radiotherapy.

Cancel claims 28-40

41. The method of claim 4, wherein said animal is a human patient.

Cancel claims 42-48

49. (New) The method of claim 4, wherein said at least a second therapeutic agent is a chemotherapeutic agent selected from the chemotherapeutic agents listed in Table B.

50. (New) The method of claim 49, wherein said at least a second therapeutic agent is cytosine arabinoside, methotrexate, aminopterin, demecolcine, mithramycin, chlorambucil, melphalan, daunorubicin, doxorubicin, verapamil, tamoxifen, taxol, vincristine, vinblastine, etoposide, 5-fluorouracil (5FU), camptothecin, actinomycin-D, mitomycin C, cisplatin, a combretastatin or cyclophosphamide.

51. (New) The method of claim 4, wherein said at least a second therapeutic agent is an anti-angiogenic agent selected from the anti-angiogenic agents listed in Table C.

52. (New) The method of claim 51, wherein said at least a second therapeutic agent is angiostatin or endostatin.

53. (New) The method of claim 4, wherein said at least a second therapeutic agent is an inflammatory cytokine.

54. (New) The method of claim 53, wherein said at least a second therapeutic agent is interleukin-4.

55. (New) The method of claim 4, wherein said at least a second therapeutic agent is H_2O_2 .

56. (New) The method of claim 4, wherein said at least a second therapeutic agent is thrombin.

57. (New) The method of claim 4, wherein said at least a second therapeutic agent is a compound that interferes with tubulin activity.

58. (New) The method of claim 57, wherein said at least a second therapeutic agent is taxol, vincristine, vinblastine, bleomycin, or a combretastatin.

59. (New) The method of claim 4, wherein said at least a second therapeutic agent is a calcium-flux inducing agent.

60. (New) The method of claim 4, wherein said at least a second therapeutic agent is a calcium ionophore.

61. (New) The method of claim 4, wherein said at least a first antibody and said at least a second therapeutic agent are administered to said animal simultaneously.

62. (New) The method of claim 4, wherein said at least a first antibody and said at least a second therapeutic agent are administered to said animal sequentially.

63. (New) The method of claim 62, wherein said at least a second therapeutic agent is administered to said animal at a biologically effective time prior to said at least a first antibody.

64. (New) The method of claim 63, wherein said at least a second therapeutic agent injures or induces apoptosis in the endothelium of the blood vessels of said vascularized tumor.

65. (New) The method of claim 64, wherein said at least a second therapeutic agent is taxol, vincristine, vinblastine, neomycin, a combretastatin, a podophyllotoxin, TNF- α , angiostatin, endostatin, vasculostatin, an $\alpha_v\beta_3$ antagonist, a calcium ionophore or a calcium-flux inducing agent; or is a prodrug thereof.

66. (New) The method of claim 62, wherein said at least a second therapeutic agent is administered to said animal at a biologically effective time subsequent to said at least a first antibody.

67. (New) The method of claim 66, wherein said at least a second therapeutic agent is an anti-tumor cell immunotoxin or an anti-angiogenic agent.

68. (New) A method for treating cancer, comprising simultaneously or sequentially administering to an animal having a vascularized tumor a therapeutically effective combination of an unconjugated antibody that binds to an aminophospholipid on the luminal surface of blood vessels of the vascularized tumor and at least a second therapeutic agent.

EXHIBIT C
REPLACEMENT SECTIONS

In the title, the addition is as shown:

COMBINED CANCER TREATMENT METHODS USING ANTIBODIES TO
AMINOPHOSPHOLIPIDS

In the title, the final text is as follows:

COMBINED CANCER TREATMENT METHODS USING ANTIBODIES TO
AMINOPHOSPHOLIPIDS

At page 1, after the heading 'Background of the Invention', in the paragraph or section of the Application pertaining to "Cross-reference to Related Applications", the deletions and additions are as shown:

The present application is a continuation of co-pending U.S. patent application Serial No. 09/351,543, filed July 12, 1999, which claims priority to first provisional application Serial No. 60/092,672, filed July 13, 1998, and second provisional application Serial No. 60/110,608, filed December 02, 1998, the entire text and figures of which applications are incorporated herein by reference without disclaimer. The U.S. Government owns rights in the present invention pursuant to grant numbers 1RO1CA74951-01 and 5RO1CA54168-05 from the National Institutes of Health.

At page 1, after the heading 'Background of the Invention', in the paragraph or section of the Application pertaining to "Cross-reference to Related Applications", the final text is as follows:

The present application is a continuation of co-pending U.S. patent application Serial No. 09/351,543, filed July 12, 1999, which claims priority to first provisional application Serial No. 60/092,672, filed July 13, 1998, and second provisional application Serial No. 60/110,608, filed December 02, 1998, the entire text and figures of which applications are incorporated herein by reference without disclaimer. The U.S. Government owns rights in the present invention pursuant to grant numbers 1RO1CA74951-01 and 5RO1CA54168-05 from the National Institutes of Health.

EXHIBIT D
ALLOWED CLAIMS
Serial No. 09/351,543 (4001.002200; UTSD:549)

1. (Amended) A method for killing tumor vascular endothelial cells, comprising administering to an animal having a vascularized tumor at least a first antibody, or antigen-binding region thereof, that binds to an aminophospholipid on the luminal surface of tumor vascular endothelial cells in an amount effective to kill said tumor vascular endothelial cells.
2. A method for inducing coagulation in tumor vasculature, comprising administering to an animal having a vascularized tumor a vessel-occluding amount of at least a first antibody, or antigen-binding region thereof, that binds to an aminophospholipid on the luminal surface of tumor vasculature.
3. (Amended) A method for treating an animal having a vascularized tumor, comprising administering to said animal a tumor-destructive amount of at least a first antibody, or antigen-binding region thereof, that binds to an aminophospholipid on the luminal surface of tumor vasculature.
4. A method for treating an animal having a vascularized tumor, comprising administering to said animal a therapeutically effective amount of at least a first pharmaceutical composition comprising at least a first antibody, or antigen-binding fragment thereof, that binds to an aminophospholipid on the luminal surface of blood vessels of the vascularized tumor.
5. The method of claim 4, wherein said pharmaceutical composition comprises at least a first antibody, or antigen-binding fragment thereof, that binds to phosphatidylethanolamine on the luminal surface of blood vessels of the vascularized tumor.
6. The method of claim 4, wherein said pharmaceutical composition comprises at least a first antibody, or antigen-binding fragment thereof, that binds to phosphatidylserine on the luminal surface of blood vessels of the vascularized tumor.
7. The method of claim 4, wherein said pharmaceutical composition comprises at least a first IgG or IgM anti-aminophospholipid antibody.

8. The method of claim 4, wherein said pharmaceutical composition comprises at least a first scFv, Fv, Fab', Fab or F(ab')₂ antigen-binding fragment of an anti-aminophospholipid antibody.

9. The method of claim 4, wherein said pharmaceutical composition comprises at least a first human, humanized or part-human chimeric anti-aminophospholipid antibody or antigen-binding fragment thereof.

10. The method of claim 4, wherein said pharmaceutical composition comprises at least a first anti-aminophospholipid monoclonal antibody or antigen-binding fragment thereof.

11. The method of claim 10, wherein said pharmaceutical composition comprises at least a first anti-aminophospholipid monoclonal antibody, or antigen-binding fragment thereof, that is prepared by a preparative process comprising:

- (a) preparing an anti-aminophospholipid antibody-producing cell; and
- (b) obtaining an anti-aminophospholipid monoclonal antibody from said antibody-producing cell.

12. The method of claim 11, wherein said anti-aminophospholipid antibody-producing cell is obtained from a human patient having a disease associated with the production of anti-aminophospholipid antibodies.

13. The method of claim 11, wherein said anti-aminophospholipid antibody-producing cell is obtained by stimulating a mixed population of human peripheral blood lymphocytes with an immunogenically effective amount of an aminophospholipid sample.

14. The method of claim 11, wherein said anti-aminophospholipid antibody-producing cell is obtained by immunizing an animal with an immunogenically effective amount of an aminophospholipid sample.

15. The method of claim 14, wherein said anti-aminophospholipid antibody-producing cell is obtained by immunizing a transgenic mouse that comprises a human antibody library with an immunogenically effective amount of an aminophospholipid sample.

16. The method of claim 11, wherein said preparative process comprises:

- (a) fusing said anti-aminophospholipid antibody-producing cell with an immortal cell to prepare a hybridoma that produces an anti-aminophospholipid monoclonal antibody; and
- (b) obtaining an anti-aminophospholipid monoclonal antibody from said hybridoma.

17. The method of claim 11, wherein said preparative process comprises:

- (a) immunizing an animal with an immunogenically effective amount of an aminophospholipid sample;
- (b) preparing a collection of antibody-producing hybridomas from the immunized animal;
- (c) selecting from the collection a hybridoma that produces an anti-aminophospholipid antibody; and
- (d) culturing the selected hybridoma to provide the anti-aminophospholipid monoclonal antibody.

18. The method of claim 17, wherein an antigen-binding region of the anti-aminophospholipid monoclonal antibody is operatively attached to a human antibody framework or constant region.

19. The method of claim 17, wherein the immunized animal is a transgenic mouse that comprises a human antibody library and wherein the anti-aminophospholipid monoclonal antibody is a human monoclonal antibody.

20. The method of claim 11, wherein said preparative process comprises:

- (a) obtaining anti-aminophospholipid antibody-encoding nucleic acids from said anti-aminophospholipid antibody-producing cell; and
- (b) expressing said nucleic acids to obtain a recombinant anti-aminophospholipid monoclonal antibody.

21. The method of claim 11, wherein said preparative process comprises:

- (a) immunizing an animal with an immunogenically effective amount of an aminophospholipid sample;
- (b) preparing a combinatorial immunoglobulin phagemid library expressing RNA isolated from the spleen of the immunized animal;
- (c) selecting from the phagemid library a clone that expresses an anti-aminophospholipid antibody; and
- (d) expressing an anti-aminophospholipid antibody-encoding nucleic acid from said selected clone to provide a recombinant anti-aminophospholipid monoclonal antibody.

22. The method of claim 21, wherein the immunized animal is a transgenic mouse that comprises a human antibody library and wherein the recombinant anti-aminophospholipid monoclonal antibody is a recombinant human monoclonal antibody.

23. The method of claim 4, wherein said pharmaceutical composition comprises a dimer, trimer or multimer of an anti-aminophospholipid antibody or antigen-binding fragments thereof.

24. The method of claim 4, wherein at least a second antibody that binds to an aminophospholipid, or an antigen-binding fragment thereof, is administered to said animal.

25. The method of claim 4, wherein said pharmaceutical composition is administered to said animal via intravenous administration.

26. The method of claim 4, wherein an image of the vasculature of said vascularized tumor is first obtained by administering to said animal a diagnostically effective amount of a detectably-labeled antibody, or antigen-binding fragment thereof, that binds to and identifies an aminophospholipid on the luminal surface of blood vessels of the vascularized tumor.

27. The method of claim 4, further comprising subjecting said animal to surgery or radiotherapy.

28. The method of claim 4, further comprising simultaneously or sequentially administering to said animal a therapeutically effective amount of at least a second anti-cancer agent.

29. The method of claim 28, wherein said at least a second anti-cancer agent is a chemotherapeutic, radiotherapeutic, anti-angiogenic or apoptosis-inducing agent.

30. The method of claim 28, wherein said at least a second anti-cancer agent is an antibody-therapeutic agent construct comprising a targeting antibody, or antigen-binding fragment thereof, that binds to a surface-expressed, surface-accessible or surface-localized component of a tumor cell, tumor stroma or tumor vasculature; said targeting antibody or fragment thereof operatively linked to a therapeutic agent.

31. The method of claim 30, wherein said targeting antibody, or antigen-binding fragment thereof, binds to a cell surface antigen of a tumor cell.

32. The method of claim 30, wherein said targeting antibody, or antigen-binding fragment thereof, binds to a component of tumor stroma.

33. The method of claim 30, wherein said targeting antibody, or antigen-binding fragment thereof, binds to a surface-expressed, surface-accessible, surface-localized, cytokine-inducible or coagulant-inducible component of intratumoral blood vessels of a vascularized tumor.

34. The method of claim 33, wherein said targeting antibody, or antigen-binding fragment thereof, binds to a surface-expressed component of intratumoral vasculature selected from the group consisting of an aminophospholipid, endoglin, a TGF β receptor, E-selectin, P-selectin, VCAM-1, ICAM-1, PSMA, a VEGF/VPF receptor, an FGF receptor, a TIE, $\alpha_v\beta_3$ integrin, pleiotropin, endosialin and an MHC Class II protein.

35. The method of claim 33, wherein said targeting antibody, or antigen-binding fragment thereof, binds to a surface-localized component of intratumoral vasculature selected from the group consisting of VEGF/VPF, FGF, TGF β , a ligand that binds to a TIE, a tumor-associated fibronectin isoform, scatter factor/hepatocyte growth factor (HGF), platelet factor 4 (PF4), PDGF and TIMP.

36. The method of claim 30, wherein said targeting antibody, or antigen-binding fragment thereof, is operatively linked to a cytotoxic agent.

37. The method of claim 36, wherein said targeting antibody, or antigen-binding fragment thereof, is operatively linked to a plant-, fungus- or bacteria-derived toxin.

38. The method of claim 37, wherein said targeting antibody, or antigen-binding fragment thereof, is operatively linked to deglycosylated ricin A chain.

39. The method of claim 30, wherein said targeting antibody, or antigen-binding fragment thereof, is operatively linked to a coagulation factor or to an antibody, or antigen-binding fragment thereof, that binds to a coagulation factor.

40. The method of claim 39, wherein said targeting antibody, or antigen-binding fragment thereof, is operatively linked to Tissue Factor, truncated Tissue Factor or a derivative thereof, or to an antibody, or antigen-binding fragment thereof, that binds to Tissue Factor, truncated Tissue Factor or a derivative thereof.

41. The method of claim 4, wherein said animal is a human patient.

42. A method for treating cancer, comprising administering to an animal having a vascularized tumor a therapeutically effective amount of at least a first pharmaceutical composition comprising at least a first naked antibody, or antigen-binding fragment thereof, that binds to an aminophospholipid on the luminal surface of intratumoral blood vessels of the vascularized tumor.

43. (Amended) A method for treating cancer, comprising administering to an animal having a vascularized tumor at least a first pharmaceutical composition comprising an amount of at least a first unconjugated antibody effective to kill at least a portion of the tumor or tumor vasculature; wherein said first unconjugated antibody is an unconjugated antibody, or antigen-binding fragment thereof, that binds to an aminophospholipid expressed on the luminal surface of tumor vascular endothelial cells.

44. A method for treating cancer, comprising administering to an animal having a vascularized tumor at least a first pharmaceutical composition comprising an amount of at least a first unconjugated antibody effective to occlude or destroy tumor blood vessels, as opposed to normal blood vessels; wherein said first unconjugated antibody is an unconjugated antibody, or antigen-binding fragment thereof, that binds to an aminophospholipid expressed on the luminal surface of tumor vascular endothelial cells.

45. A method for treating cancer, comprising administering to an animal having a vascularized tumor at least a first pharmaceutical composition comprising an amount of at least a first unconjugated antibody effective to induce tumor necrosis; wherein said first unconjugated antibody is an unconjugated antibody, or antigen-binding fragment thereof, that binds to an aminophospholipid expressed on the luminal surface of blood vessels of the vascularized tumor.

46. A method for treating cancer, comprising:

- (a) forming an image of a vascularized tumor by administering to an animal having a vascularized tumor a diagnostically effective amount of a detectably-labeled antibody, or antigen-binding fragment thereof, that binds to an aminophospholipid on the luminal surface of blood vessels of the vascularized tumor, thereby forming a detectable image of the tumor vasculature; and
- (b) subsequently administering to said animal a therapeutically effective amount of at least a first antibody, or antigen-binding fragment thereof, that binds to an aminophospholipid on the tumor blood vessel luminal surface and thereby destroys the tumor vasculature.

47. A method for treating cancer, comprising simultaneously or sequentially administering to an animal having a vascularized tumor a therapeutically effective combination of an unconjugated antibody, or antigen-binding fragment thereof, that binds to an aminophospholipid on the luminal surface of blood vessels of the vascularized tumor and at least a second anti-cancer agent.

48. The method of claim 47, wherein said at least a second anti-cancer agent is a chemotherapeutic, radiotherapeutic, anti-angiogenic or apoptosis-inducing agent or an antibody-therapeutic agent construct comprising a therapeutic agent operatively attached to an antibody, or antigen-binding fragment thereof, that binds to a surface-expressed, surface-accessible, surface-localized, cytokine-inducible or coagulant-inducible component of tumor vasculature or tumor stroma.

49. A method for inducing cell death in tumor vascular endothelial cells, comprising administering to an animal having a vascularized tumor at least a first antibody, or antigen-binding region thereof, that binds to an aminophospholipid on the luminal surface of tumor vascular endothelial cells in an amount effective to induce cell death in tumor vascular endothelial cells.

50. A method for treating an animal having a vascularized tumor, comprising administering to said animal at least a first antibody, or antigen-binding region thereof, that binds to an aminophospholipid on the luminal surface of tumor blood vessels in an amount effective to destroy or occlude at least a portion of said tumor blood vessels upon binding to said aminophospholipid.

51. (New) A method for killing tumor vascular endothelial cells, comprising administering to an animal having a vascularized tumor at least a first antibody that binds to an aminophospholipid on the luminal surface of tumor vascular endothelial cells in an amount effective to kill said tumor vascular endothelial cells.

52. (New) A method for inducing coagulation in tumor vasculature, comprising administering to an animal having a vascularized tumor a vessel-occluding amount of at least a first antibody that binds to an aminophospholipid on the luminal surface of tumor vasculature.

53. (New) A method for treating an animal having a vascularized tumor, comprising administering to said animal a tumor-destructive amount of at least a first antibody that binds to an aminophospholipid on the luminal surface of tumor vasculature.

54. (New) A method for treating an animal having a vascularized tumor, comprising administering to said animal a therapeutically effective amount of at least a first pharmaceutical composition comprising at least a first antibody that binds to an aminophospholipid on the luminal surface of blood vessels of the vascularized tumor.

55. (New) The method of claim 54, wherein said pharmaceutical composition comprises at least a first antibody that binds to phosphatidylserine on the luminal surface of blood vessels of the vascularized tumor.

56. (New) The method of claim 54, wherein said animal is a human patient.

57. (New) A method for treating cancer, comprising administering to an animal having a vascularized tumor a therapeutically effective amount of at least a first pharmaceutical composition comprising at least a first naked antibody that binds to an aminophospholipid on the luminal surface of intratumoral blood vessels of the vascularized tumor.

58. (New) A method for treating cancer, comprising administering to an animal having a vascularized tumor at least a first pharmaceutical composition comprising an amount of at least a first unconjugated antibody effective to kill at least a portion of the tumor or tumor vasculature; wherein said first unconjugated antibody binds to an aminophospholipid expressed on the luminal surface of tumor vascular endothelial cells.

59. (New) A method for treating cancer, comprising administering to an animal having a vascularized tumor at least a first pharmaceutical composition comprising an amount of at least a first unconjugated antibody effective to occlude or destroy tumor blood vessels, as opposed to normal blood vessels; wherein said first unconjugated antibody binds to an aminophospholipid expressed on the luminal surface of tumor vascular endothelial cells.

60. (New) A method for treating cancer, comprising administering to an animal having a vascularized tumor at least a first pharmaceutical composition comprising an amount of at least a first unconjugated antibody effective to induce tumor necrosis; wherein said first unconjugated antibody is an unconjugated antibody that binds to an aminophospholipid expressed on the luminal surface of blood vessels of the vascularized tumor.

61. (New) A method for treating cancer, comprising simultaneously or sequentially administering to an animal having a vascularized tumor a therapeutically effective combination of an unconjugated antibody that binds to an aminophospholipid on the luminal surface of blood vessels of the vascularized tumor and at least a second anti-cancer agent.

62. (New) A method for inducing cell death in tumor vascular endothelial cells, comprising administering to an animal having a vascularized tumor at least a first antibody that binds to an aminophospholipid on the luminal surface of tumor vascular endothelial cells in an amount effective to induce cell death in tumor vascular endothelial cells.

63. (New) A method for treating an animal having a vascularized tumor, comprising administering to said animal at least a first antibody that binds to an aminophospholipid on the luminal surface of tumor blood vessels in an amount effective to destroy or occlude at least a portion of said tumor blood vessels upon binding to said aminophospholipid.

Phosphatidylserine is a marker of tumor vasculature and a potential target for anti-cancer drugs¹

Sophia Ran², Neal Rote³ and Philip E. Thorpe²

Simmons Comprehensive Cancer Center, UT Southwestern Medical Center,
2201 Inwood, Dallas, Texas 75390-8594 and the Department of Pharmacology
UT Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-9111

Running title: PS is a marker of tumor vessels

Key words: Phosphatidylserine, tumor endothelium, apoptosis, tumor targeting

¹ This work was supported in part by NIH grants 1R01CA74951-01 and 5R01CA54168-05, and by Susan G. Komen Breast Cancer Foundation grant BCTR 2000 269

² To whom correspondence should be addressed at 2201 Inwood Road, NC7.304, Dallas, Texas 75390-8594. Phone: (214) 648-1628; Fax: (214) 648-1613; E-mail: sophia.ran@utsouthwestern.edu

³ Dept. Microbiology and Immunology, Wright State University, Dayton, OH 45435

Abbreviations used in this paper are: TF, tissue factor; VCAM-1, vascular cell adhesion molecule 1; IL-1 α , interleukin-1 alpha; DPBS, Dulbecco's phosphate buffered saline; HRP, horseradish peroxidase; AP, alkaline phosphatase; SMC, smooth muscle cells; SCID, severe combined immunodeficient; PS, Phosphatidylserine; CL, cardiolipin; ROS, reactive oxygen species.

ABSTRACT

Phosphatidylserine (PS) is a phospholipid that almost exclusively resides on the inner leaflet of the plasma membrane under normal conditions. PS translocation to the external side of the membrane (PS exposure) is associated with apoptosis, necrosis, cell injury, cell activation and malignant transformation. We previously reported that endothelial cells in tumor vessels of Hodgkin's lymphoma implanted in mice express PS on their external surface. Endothelial cells in normal tissues did not express detectable amounts of PS. In the present study, we analyzed five additional tumor models for the exposure of PS on tumor vasculature and investigated a potential mechanism underlying this phenomenon. Anti-PS antibody specifically localized to tumor blood vessels in all tumors (HT29 human colon adenocarcinoma, NCI-H358 human lung carcinoma, B16 mouse melanoma, 3LL mouse lung carcinoma and Colo 26 mouse colon carcinoma). No localization was detected on normal endothelium. An isotype-matched control antibody directed against a different negatively charged lipid, cardiolipin, did not localize to either tumor or normal endothelium. Frozen tumor sections were examined for the presence of apoptotic cells, using a double labeling technique that detected a pan-endothelial cell marker and the apoptosis markers, active caspase 3 and fragmented DNA (Tunel assay). Neither apoptosis marker was present in tumor endothelium, indicating that PS-positive tumor vessels are seldom apoptotic. Externalization of PS also did not correlate with the maturation status of the vessels, as an abnormal pericytic network was equally evident around PS-positive and PS-negative tumor vessels. Various factors and tumor-associated conditions known to be present in the tumor microenvironment were examined for their ability to cause PS translocation in cultured endothelial cells. Hypoxia/reoxygenation, acidity, thrombin, and inflammatory cytokines all induced PS exposure without causing cytotoxicity. Hydrogen peroxide was also a strong inducer. Possibly, conditions inside tumors generate reactive

oxygen species that induce PS exposure. Combined treatment with inflammatory cytokines and hypoxia/reoxygenation had greater than additive effects, suggesting that factors may interact to give amplified effects on PS-exposure on tumor endothelium *in vivo*. Since PS is absent from the outer surface of normal endothelium, its exposure on tumor vessels could potentially be utilized for tumor vessel targeting and imaging.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204
2205
2206
2207
2208
2209
2210
2211
2212
2213
2214
2215
2216
2217
2218
2219
2220

INTRODUCTION

Phosphatidylserine (PS) is a phospholipid that almost exclusively resides in the inner leaflet of the plasma membrane under normal conditions (1; 2). PS asymmetry is maintained by an ATP-dependent aminophospholipid translocase that is responsible for inward movement of aminophospholipids (3-5). Loss of PS asymmetry results from the outward movement of PS in the plasma membrane and is caused either by inhibition of the translocase (6; 7) or activation of scramblase, a Ca^{2+} dependent enzyme that transports lipids bidirectionally (8; 9). Loss of PS asymmetry is observed under different pathological and physiological conditions, including programmed cell death (10; 11), cell aging (12), intercellular fusion of myoblasts (13) and trophoblasts (14), cell migration (15; 16), activation of platelets (17-19) and cell degranulation (20). Endothelial cells externalize PS in response to thrombin (21) hyperlipidemia (22), viral infection (23), non-lytic concentrations of complement proteins C5b-9 (24) or exposure to calcium ionophore A23187 and PMA (25). Spontaneous PS exposure has been also observed in malignant cells in the absence of exogenous activators or cell injury (26-28).

Several major consequences follow membrane PS exposure. Phagocytic macrophages recognize, attach and eliminate PS-positive senescent and apoptotic cells (29; 30). PS also mediates attachment of T lymphocytes to thrombin-activated endothelial cells (21). The complement system is activated by PS and contributes to the lysis of PS-positive cells (31). Finally, PS exposure contributes to a procoagulant shift on the endothelium (1; 11) by providing a negatively charged lipid surface for assembly and activation of coagulation complexes (32; 33).

A mouse monoclonal IgM, 3SB, directed against PS has been raised and characterized by Rote and colleagues (17). The antibody binds to PS but not to phosphatidylcholine, phosphatidylethanolamine or cardiolipin (CL). 3SB binds to PS-coated ELISA plates in the presence or absence of serum, indicating that PS binding does not require cofactors. 3SB binds to cells having exposed PS (17). It is possible that it recognizes hexagonally packed PS, which has been reported to be antigenic (34).

We previously discovered that 3SB localized to tumor blood vessels in mice bearing human Hodgkin's disease tumors. This finding indicated that endothelial cells in Hodgkin's tumors, in contrast to those in normal tissues, expressed PS on the external surface of their plasma membrane. In the present study, we determined whether vascular PS exposure is observed in other types of tumors, and investigated the causes of PS translocation. PS exposure on tumor vasculature was present in all of six different tumors growing in mice. PS exposure was not due to apoptosis of tumor endothelium, or to irregularities in their coating with perivascular cells. Studies with cultured endothelial cells showed that hypoxia/reoxygenation, acidity, thrombin, and inflammatory cytokines caused PS exposure without causing cytotoxicity. Hydrogen peroxide did likewise. Hypoxia/reoxygenation, acidity, thrombin and inflammatory cytokines may therefore act individually or collectively in tumors to generate peroxide ions and other reactive oxygen species that induce PS exposure on tumor endothelium.

PS on tumor vessels may provide a target molecule for the vascular targeting or imaging of vessels in solid tumors. Annexin V, an endogenous PS-binding ligand, has been used successfully to image PS-expressing activated platelets in thrombi (35), apoptotic cells in rejecting cardiac allografts, cyclophosphamide-treated lymphomas and anti-Fas antibody-

treated livers in rodents (10). Anti-PS antibodies may be directly cytotoxic to tumor vasculature, or mediate the binding of cytotoxic or coagulation factor to tumor vessels complement, host cells. Also, anti-PS antibodies, annexin V and other ligands that bind specifically to PS on tumor endothelial cells might be used to deliver a cytotoxic drug, radionuclide or coagulant to tumor vessels. Vascular targeting agents directed against markers on mature blood-transporting vessels in tumors have caused destruction of tumor vasculature and major tumor regressions in other systems (36-38). The present studies suggest the use of PS-directed antibodies and immunoconjugates for the vascular targeting or imaging of tumor vessels in man.

MATERIALS AND METHODS

Materials. Na¹²⁵I was obtained from Amersham (Arlington Heights, IL). Dulbecco's modified Eagle's tissue culture medium and Dulbecco PBS containing Ca²⁺ and Mg²⁺ were obtained from Gibco (Grand Island, NY). Fetal calf serum was obtained from Hyclone (Logan, Utah). O-phenylenediamine, hydrogen peroxide and thrombin were from Sigma (St. Louis, MO). Flat bottom plates with 24 wells were obtained from Falcon (Becton Dickinson and Co., Lincoln Park, NJ). Recombinant murine interleukin-1 alpha, beta and tumor necrosis factor alpha (TNF α) were purchased from R&D Systems (Minneapolis, MN). Interferon of Universal Type I (hybrid protein that substitutes for all types of interferons) was purchased from PBL Biomedical Laboratories (New Brunswick, NJ). Recombinant hepatocyte growth factor (HGF or scatter factor) and actinomycin D were from Calbiochem. Recombinant VEGF, PDGF-BB, TGF β ₁, interleukin-6 (IL-6),

interleukin-8 (IL-8), interleukin-10 (IL-10) and FGF-1 were purchased from PeproTech (Rocky Hill, NJ).

Antibodies

Mouse monoclonal anti-PS and anti-CL IgM antibodies were raised as described (17). Both antibodies have been extensively characterized with regard to the specificity of their binding to PS and CL respectively (17). MECA 32, a pan mouse endothelial cell antibody, was kindly provided by Dr. E. Butcher (Stanford University, CA) and served as a positive control for immunohistochemical studies. Details of this antibody have been published (39). Rabbit anti-rat immunoglobulin, rat-anti mouse immunoglobulin and goat-anti mouse immunoglobulin secondary antibodies conjugated to horseradish peroxidase (HRP) or alkaline phosphatase (AP) were purchased either from Daco (Carpinteria, CA) or from Jackson ImmunoResearch Labs (West Grove, PA).

Cells

L540Cy Hodgkin lymphoma cells, derived from a patient with end-stage disease, were provided by Prof. V. Diehl (Köln, Germany). HT29 human colon adenocarcinoma and NCI-H358 human non-small cell lung carcinoma were provided by Dr. Adi Gazdar (Southwestern Medical Center, Dallas, TX). B16 mouse melanoma and 3LL mouse lung carcinoma were obtained from American Type Cell Collection (Rockville, MD). Colo 26 mouse colorectal carcinoma was a gift from Dr. Ian Hart (ICRF, London, UK). The mouse brain endothelioma, bEnd.3, was provided by Prof. Werner Risau (Max Plank Institution, Munich, Germany).

METHODS

Tissue Culture

bEnd.3 cells, adult bovine aortic endothelial (ABAE) cells and all tumor cells except L540Cy lymphoma cells were maintained in DMEM supplemented with 10% fetal calf serum, 2 mM L-glutamine, 2 units/ml penicillin G and 2 ug/ml streptomycin. L540Cy cells were maintained in RPMI 1640 containing the same additives. Cells were sub-cultured once a week. Trypsinization of bEnd.3 cells was performed using 0.125% trypsin in PBS containing 0.2% EDTA. For *in vitro* studies, endothelial cells were seeded at a density of 1×10^4 cells/ml in 1 ml of culture medium in 24 well plates and incubated 48-96 hours before being used in the assays. Medium was refreshed 24 hours before each experiment.

Growth of tumor cells *in vivo*

For localization studies, 2×10^7 L540 human Hodgkin's lymphoma cells or 1×10^7 cells of other tumor types were injected subcutaneously into the right flank of SCID mice (Charles River, Wilmington, MA). Tumors were allowed to reach a volume of 0.4-0.7 cm³. A minimum of three animals per tumor group was used. Experiments were performed at least three times.

Detection of PS exposure on tumor endothelium *in vivo*

Detection of exposed PS *in vivo* was performed essentially as previously described (37). Briefly, anti-PS or anti-CL mouse IgM antibodies (30 ug/mouse) were injected intravenously in 200 ul of saline. Thirty minutes later mice were sacrificed and their blood circulation was exsanguinated and perfused with heparinized saline as previously described (40). All major organs and tumor were harvested and snap-frozen for preparation of

cryosections. Mouse IgM was detected using goat anti mouse IgM (μ specific) - HRP conjugate followed by development with carbazole (41). The number of positive vessels per high power field was determined at magnification of x 40. At least 10 random fields per section were examined and the average percentage of positive vessels was calculated.

Detection of apoptosis in tumors *in situ*

The blood circulation of mice was perfused with heparinized saline as previously described (40). Tumors were dissected out and snap-frozen for cryosectioning. Cytosolic and nuclear alterations characteristic for apoptotic cells were detected immunohistochemically by using two markers: active caspase-3 (42) and fragmented DNA (43). Active caspase-3 was detected by a rabbit anti-caspase-3 specific antibody (R&D, Minneapolis, MN) followed by incubation with anti-rabbit IgG conjugated to alkaline phosphatase (AP, Pierce, Rockford, IL). Other tumor sections were analyzed by Tunel assay (ApopTag kit, Oncor, MD) using anti-digoxigenin-alkaline phosphatase conjugate as a detecting reagent. To determine whether tumor endothelial cells express apoptotic markers, sections were sequentially labeled with MECA 32 (anti-endothelial marker) and anti rat-HRP secondary antibody, followed by either anti-caspase-3 antibody or Tunel assay and AP-conjugated secondary reagents. Vessels were visualized by their brown color, using Stable DAB (Research Genetics, Huntsville, AL) as a substrate. Apoptotic cells were identified by their pink-purple color (kit from Research Genetics) created by the phosphatase activity of secondary reagents detecting markers of apoptosis. The pink-purple stain was clearly distinguishable from the brown stain, if both markers coincided. These conditions of double labeling permitted the sequential detection of both enzymes.

Detection of pericytes on tumor frozen sections

To characterize interactions between PS-positive vessels and pericytes, tumor sections were double-labeled by goat anti mouse IgM-HRP (to identify anti-PS localized antibody) followed by anti α -smooth muscle cell actin (α -SMC) antibody (Daco, Carpinteria, CA), a marker of pericytes and vascular smooth muscle cells (SMC)(44; 45). The peroxidase activity was detected by Stable DAB and resulted in brown color. The pericytic marker was detected by anti mouse IgG-AP conjugate and resulted in a pink-purple color. Substrates for both enzymes were from Research Genetics. In other experiments, the endothelium was first detected by MECA 32 IgG and visualized by DAB, followed by anti α -SMC antibody and AP-mediated detection of pericytes/SMC.

Iodination of annexin V

Recombinant human annexin V was purified from *E. coli* transformed with ET12a-PAP1 plasmid (a gift from Dr. J. Tait, University of Washington, Seattle). The purity of the protein and the binding to PS were confirmed on SDS-PAGE and on PS-coated plastic, respectively. Rabbit polyclonal, affinity-purified anti-annexin V antibody was used to detect annexin V bound to PS. Annexin V was radiolabeled with ^{125}I using Chloramine T as described by Bocci (46). The specific activity was approximately 1×10^6 cpm per μg of protein, as measured by a Bradford assay (47).

Effect of growth factors, cytokines, inflammatory mediators, hydrogen peroxide, hypoxia and acidic pH on translocation of PS in cultured endothelial cells

Endothelial cells were treated with cytokines or growth factors at the concentrations listed in Table 3. All reagents were diluted in medium containing 10% serum and incubated with the cells at 37°C for 24 hours. To study the effect of hypoxia, cells were seeded on 24 well

plates and were incubated in a humidified normoxic atmosphere (21% O₂, 5% CO₂) for 48 hours before being transferred to a humidified hypoxic atmosphere (1% O₂, 5% CO₂, 94% N₂) in a sealed chamber (Billups Rothenberg inc, Del Mar, Ca). Cells were incubated in a hypoxic chamber for 24 hours at 37°C and the cells were compared to a parallel culture maintained under normoxic conditions. In some experiments, IL-1 α (10 ng/ml) and TNF α (20 ng/ml) were added to medium prior to transfer to a hypoxic chamber.

To examine the effect of an acidic microenvironment, cells were exposed to the growth medium lacking bicarbonate, which was adjusted to different pHs (ranged between 7.3 to 6.2) with the required amount of HCl. Cells were incubated at 37°C in the absence of CO₂. Preservation of the medium pH in the presence of cell monolayer during 24 hours period was confirmed in each experiment. Under these experimental conditions all tested reagents were non-toxic to either bovine or mouse endothelial cells and had no effect on cell morphology or viability of the attached monolayer.

Detection of exposed PS on cultured endothelial cells by ¹²⁵I-labeled annexin V

After treatment with the reagents described above, treated and control cells were incubated with 7.1 pmoles of ¹²⁵I-labeled annexin V (200 μ l/well) in the binding buffer. After 2 hours incubation at room temperature, cells were washed extensively and dissolved in 0.5 M of NaOH. The entire volume of 0.5 ml was transferred to plastic tubes and counted in a gamma counter. Non-specific binding was determined in the presence of 5 mM EDTA and was subtracted from experimental values. The results were expressed as net pmoles of cell-bound annexin V, normalized per 1×10^6 cells. Maximal binding of annexin V was determined on cells simultaneously treated with actinomycin D and TNF α (50 ng/ml of each component). As has been previously reported, combination of the above agents causes apoptosis and PS exposure in the 100 percent of the treated endothelial cells (48).

Basal binding of ^{125}I -annexin V to untreated cells was determined in the presence of medium with 10% serum. The amount of ^{125}I -annexin V that bound to the untreated cultures was subtracted from that in the treated cultures. The specific increase in the amount of externalized PS was calculated according to the following formula: (net experimental binding / net maximal binding) X 100. Each experiment was performed in duplicate and was performed at least three times.

Detection of exposed PS on endothelial cells *in vitro* by biotinylated annexin V

Endothelial monolayers were washed with DPBS containing Ca^{2+} and Mg^{2+} and fixed with 0.25% of glutaraldehyde diluted in the same buffer. Excess aldehyde groups was quenched by incubation with 50 mM of Na_4Cl for 5 minutes. Cells were washed with DPBS (containing Ca^{2+} , Mg^{2+} and 0.2% gelatin) and incubated with 1 $\mu\text{g}/\text{ml}$ of biotinylated annexin V (Pharmingen, San Diego, CA). After 2 hours of incubation, cells were washed with 0.2% gelatin buffer incubated with streptavidin-HRP (1:500 dilution). Detection of PS *in situ* was confirmed by staining with anti-PS IgM. Anti-CL IgM and streptavidin were used as negative controls in these assays. All steps were performed at room temperature. PS-positive cells were detected by addition of carbazole substrate, resulting in insoluble red-brownish precipitate. The number of positive cells per high power field was determined and expressed as a percent of the total number of cells. Six random fields were scored per well and the average was calculated.

RESULTS

PS is a marker of tumor vasculature.

PS exposure on vascular endothelium *in vivo* was detected by a specific anti-PS mouse IgM, (3SB) as previously described (37). A class and species matched antibody, D11 (17),

directed against a different negatively charged phospholipid, CL, served as a negative control. CL exclusively resides in the membrane of mitochondria (49). This anti-CL monoclonal antibody recognizes CL, not PS or other lipids (17).

All six tumors included in this study contained PS-positive vessels (Fig.1 and Table 1). The percentage of PS-positive vessels ranged from 40% in B16 tumors to 10% in Colo 26 tumors. Anti-PS IgM was present on the luminal surface of capillaries and venules in all regions of the tumors. PS-positive vessels appeared to be particularly prevalent in and around regions of necrosis. Positive vessels usually did not show morphological abnormalities that were apparent by light microscopy. Occasional vessels located in necrotic areas showed morphological signs of deterioration. Detection of PS by 3SB was specific since no staining of tumor endothelium was observed with the anti-CL antibody. Anti-PS antibody (but not anti-CL antibody) also localized to necrotic and apoptotic tumor cells. No vascular localization of anti-PS or anti-CL antibodies was observed in normal organs other than the kidneys (Table 1). In the kidneys, tubules were stained in both anti-PS and anti-CL recipients, presumably because of secretion of IgM through this organ. These findings demonstrate that PS is present on the luminal surface of vascular endothelial in various tumors but not in normal tissues.

PS-positive tumor vessels are not apoptotic

A double labeling technique was used to identify apoptotic endothelial cells in tumor sections. Apoptotic cells were identified with two independent markers: an active form of caspase-3, which identifies cytosolic changes in dying cells (42), and fragmented DNA, which identifies cells having nuclear alterations (43). Active caspase-3 was detected by a specific antibody. Fragmented DNA was visualized by TUNEL assay (43). Cells positive for apoptotic markers were stained pink by AP-labeled secondary reagents. Endothelial cells in blood vessels were stained brown by HRP-labeled by a pan-endothelial antibody, MECA

32. Both colors were clearly visible on the same cells, if endothelial and apoptotic markers coincided.

Endothelial cells in five out of six types of tumors (HT29, H358, B16, Colo 26, L540) did not display either of the apoptosis markers (Fig. 2, Table 2). The sixth type of tumor, 3LL, displayed a few apoptotic endothelial cells that were located in necrotic areas. In contrast, apoptotic malignant cells were common in all types of tumors. The percentage of apoptotic tumor cells ranged from 1-2% in L540 tumors to 12.6-19.6% in 3LL tumors. There was broad correspondence between the number and location of tumor cells that stained positively for active caspase 3 and for fragmented DNA. However, cells displaying active caspase 3 were about 1.5 times as abundant as those with fragmented DNA, probably because active caspase 3 is an earlier and less specific marker of apoptosis than is fragmented DNA.

Lack of correlation between PS-positive tumor vessels and abnormal distribution of pericytes

We explored whether abnormalities in the perivascular cell coating of tumor vessels might account for their PS exposure by determining whether there was a correlation between the integrity of the coating by pericytes and the positivity for externalized PS. Frozen tumor sections from mice that had been injected with anti-PS antibody or anti-CL antibody were double labeled for the presence of the vascular endothelial cell marker, MECA 32, and a pericytic cell/SMC marker, α SMC-actin. Endothelial cells were stained brown while pericytic cells were stained pink. PS-positive tumor vessels were identified in sequential sections by staining for localized anti-PS IgM (brown) followed by identification of pericytes (pink). In contrast to the continuous pericytic layer surrounding vascular

endothelial cells in normal tissues, vessels in all tumors had a discontinuous and disorganized network of pericytic cells (Fig. 3). Vessels in B16 melanomas and Colo 26 carcinomas almost completely lacked pericytes. HT29 and H358 carcinomas contained pericytes/SMC that were often totally separated from endothelial cells. The L540 lymphoma was the only tumor of those examined that had a major percentage (about 40%) of vessels in which pericytic cells were properly attached.

There was no correlation between irregularities in pericytic cells and exposure of PS on tumor vessels (Fig. 3). PS-positive and PS-negative tumor endothelium had equal proportions of coated vessels, uncoated vessels and vessels with partly detached pericytic layers. Abnormalities in pericyte coating, therefore, do not appear to be the cause of PS translocation on tumor endothelium.

Inducers of PS translocation by endothelial cells *in vitro*

Endothelial cells *in vitro* were treated with non-toxic concentrations of various factors and conditions that are present in the microenvironment of many tumors (50-54). The factors included: angiogenic factors (VEGF, HGF and bFGF) tumor and host cell-derived inflammatory and pro-angiogenic cytokines (1L-1 α , IL-1 β , TNF α , IL-6, IL-8, IL-10 and interferons), thrombin, hypoxia/reoxygenation, oxygen-reactive species and low pH. These conditions are all known to perturb endothelial cells and could be considered as potential cause of PS translocation. Activation, perturbation and injury of endothelium by these factors and conditions are associated with a rise of intracellular Ca²⁺ concentration. The rise in intracellular Ca²⁺ might activate scramblase (9) and simultaneously inhibit aminophospholipid translocase (6), leading to accumulation of PS on the external side of the membrane.

Mouse bEnd.3 or bovine ABAE cells were treated for 24 hours with different concentrations of potential inducers of PS translocation. PS externalization was quantified by measuring ^{125}I -annexin V binding. The amount of annexin V binding was compared with that of cells in which apoptosis of 100% of cells had been induced by combined treatment with actinomycin D and $\text{TNF-}\alpha$. Actinomycin D and $\text{TNF-}\alpha$ induced the binding of 6.2 pmoles of annexin V per 10^6 cells (3.8×10^6 molecules of annexin V per cell) on both cell types, in good agreement with literature reports (55). This value was taken as the maximal amount of externalized PS.

Untreated cells were largely devoid of externalized PS, as judged by annexin V or anti-PS antibody binding (Table 3, and Fig. 4A). The basal binding in the presence of growth medium alone was 0.44 and 0.68 pmoles of ^{125}I -annexin V for ABAE and bEnd.3 cells, respectively. This corresponds to 7.06% and 10.9% of the maximal binding for ABAE and bEnd.3 cells, respectively, which correlated well with the finding that approximately 10% of cells bound biotinylated annexin V under the same conditions. VEGF, HGF, FGF, $\text{TGF}\beta_1$, PDGF, IL-6, IL-8 and IL-10 did not increase binding of ^{125}I -annexin V above the basal level for untreated cells. Inflammatory mediators (IL-1 α , IL-1 β , $\text{TNF}\alpha$ and interferon) caused a small but reproducible increase in PS translocation that ranged from 6 to 8% of the maximal level for ABAE cells and from 7 to 14% for bEnd3 cells (Table 3). Hypoxia/reoxygenation, thrombin or acidic external conditions (pH 6.8-6.6) induced a moderately high externalization of PS that ranged from 8 to 20% of the maximal level for ABAE cells and from 17 to 22% of the maximal level for bend.3 cells. The largest increase in PS translocation was observed after treatment with 100 to 200 μM of hydrogen peroxide. This treatment caused nearly complete (95%) externalization of PS in both cell types as judged by ^{125}I -annexin V binding (Table 3). More than 70% of ABAE and bEnd.3

cells bound biotinylated annexin V, as judged immunohistochemically (Fig. 4B). PS-expressing endothelial cells generated by treatment with hypoxia/reoxygenation, thrombin, acidity, $\text{TNF}\alpha$, IL-1 or H_2O_2 remained attached to the matrix during time period of the assay (24 hours), retained cell-cell contact (Fig. 4B) and retained their ability to exclude trypan blue dye. Normal PS orientation was restored 24 to 48 hours later in the majority of the cells. These results indicate that mild oxidative stress, created by direct application of H_2O_2 or indirectly by hypoxia/reoxygenation, acidity, thrombin, or inflammatory cytokines, triggers a transient translocation of PS on viable endothelial cells.

Combined Effects of Inflammatory Cytokines and Hypoxia/Reoxygenation on PS-Exposure by Endothelial Cells *In Vitro*

Enhanced PS exposure was observed when ABAE cells were subjected to hypoxia/reoxygenation in the presence of IL-1 α or $\text{TNF}\alpha$. In the absence of the cytokines, hypoxia/reoxygenation increased PS-exposure by ABAE cells to 15% of the maximum level for cells treated with apoptotic concentrations of actinomycin D and $\text{TNF}\alpha$. In the presence of subtoxic concentrations of IL-1 α or $\text{TNF}\alpha$, hypoxia/reoxygenation increased PS-exposure to 26% and 33% respectively of the maximum (Fig. 5). Cytokines in the absence of hypoxia/reoxygenation increased PS-exposure by less than 7% indicating that the combination of cytokines and hypoxia/reoxygenation had greater than additive effects on PS-exposure. Thus, in tumors, the PS-inducing effect of hypoxia/reoxygenation may be amplified by inflammatory cytokines and possibly by such other stimuli as acidity and thrombin.

DISCUSSION

The major finding to emerge from this study is that vascular endothelial cells in tumors externalize PS to their luminal surface where it can be bound by a specific anti-PS antibody *in vivo*. PS is absent from the external surface of vascular endothelial cells in normal tissues, suggesting that PS-recognizing antibodies, annexin V and other ligands might be used for delivering cytotoxic drugs, coagulants or radionuclides for the selective destruction or imaging of vessels in solid tumors.

PS-positive tumor endothelium appears to be viable. It does not display markers of apoptosis, it is morphologically intact and metabolically active, as indicated by its expression of VCAM-1, E-selectin and other rapidly turned-over proteins. Although often regarded as an indicator of apoptosis, PS exposure has been observed in several types of viable cells, including malignant cells (27; 28; 55), activated platelets (17), and embryonic trophoblasts at various stages of migration, matrix invasion and fusion (14). Recent studies suggest that constitutive PS exposure on malignant cells may occur because expression of truncated (less active) aminophospholipid translocase, as detected by epitope-specific antibodies against the putative PS translocase, ATPaseII⁴. Lack of correlation between PS exposure and commitment to cell death has been also shown on pre-apoptotic B lymphoma cells that restored PS asymmetry and grew normally after removal of pro-apoptotic stimulus (56). In normal viable cells, PS exposure is probably triggered by surface events, such as ligand-receptor interactions, that induce Ca²⁺ fluxes into the cells (57). Ca²⁺ fluxes activate scramblase (9) and simultaneously inhibit aminophospholipid translocase (6).

To shed light on the mechanism of PS exposure on tumor endothelial cells, a series of experiments was performed in which endothelial cells *in vitro* were treated with various factors and conditions known to be present in the tumor microenvironment. The objective was to identify factors that induce PS exposure on endothelial cells without causing cytotoxicity in order to mimic the situation in tumors *in vivo*. Hypoxia followed by reoxygenation, acidity, and thrombin increased PS exposure on viable endothelial cells to between 10 and 22% of the level seen when all cells are apoptotic. Inflammatory cytokines (TNF α and IL-1 α) also caused a weak but definite induction of PS exposure. The possibility that these conditions are in fact the major inducing stimuli in tumors *in vivo* is suggested by the following: i) PS positive endothelium is prevalent in and around regions of necrosis where hypoxia, acidity, thrombosed blood vessels, and infiltrating host leukocytes are commonly observed; ii) the finding that hypoxia/reoxygenation amplifies the weak PS-exposing activity of TNF α and IL-1 on endothelial cells *in vitro* (Fig. 5) correlates with the situation *in vivo* in tumors where hypoxia and cytokine-secreting tumor and host cells co-exist; iii) hypoxia/reoxygenation and thrombin have been reported to generate reactive oxygen species (e.g. peroxides) in endothelial cells through activation of NADPH oxidase-like membrane enzyme (58; 59). Hydrogen peroxide was the most powerful inducer of PS exposure on cultured endothelial cells found in the present study, providing indirect support for the involvement of reactive oxygen species. Based on these findings we propose the following cascade of events leading to PS exposure on tumor vessels, which indirectly contributes to tumor-associated thrombosis (Fig. 6).

Hypoxia/reoxygenation in combination with inflammatory cytokines, thrombin and acidity are responsible in part for generation of ROS by endothelial and tumor cells. ROS are also produced by infiltrating host cells (macrophages, neutrophils and granulocytes) that are

attracted by necrosis and tumor-derived cytokines. Tumor endothelial cells respond to rising ROS concentration by transferring PS to the external side of the membrane. The externalized PS provides the negative phospholipid surface upon which coagulation factors concentrate and assemble. This confers the procoagulant status to the tumor endothelium that has long been recognized. PS also provides an attachment site for circulating macrophages (29), T lymphocytes (21) and polymorphonuclear cells that assist in leukocyte infiltration into tumors. Adherence of activated macrophages, polymorphonuclear cells and platelets to PS on tumor endothelium may lead to further secretion of reactive oxygen species and further amplification of PS exposure.

Anti-PS antibodies might be used for cancer therapy in several ways. Unconjugated antibodies might directly suppress tumor endothelial cell growth or survival by interfering with critical PS-dependent surface functions. This hypothesis is supported by the studies on viable B cells demonstrating that PS neutralization inhibits signaling from the cell surface via B cell receptor (57). Anti-PS antibodies might also mediate toxicity by binding complement and cytotoxic cells, by inducing apoptosis or by promoting pro-thrombotic status of tumor vascular endothelium. In certain autoimmune disorders, anti-aminophospholipid antibodies cause normal tissue damage by analogous mechanisms (60-62). Also, anti-PS antibodies or ligands might be linked to various effector molecules (e.g. cytotoxic drugs, radionuclides, coagulants) to create vascular targeting agents that destroy or occlude blood vessels in solid tumors. Such agents have been shown to be highly effective, and sometimes curative, in mice with large solid tumors (36; 38).

PS on tumor vessels is attractive as a target for several reasons: it is abundant (minimum of 3×10^6 molecules per cell); it is on the luminal surface of tumor endothelium, which is

directly accessible for binding by vascular targeting agents in the blood; it is present on a high percentage of tumor endothelial cells in diverse solid tumors, and it is absent from endothelium in all normal tissues examined to date. Unconjugated antibodies, vascular targeting agents and imaging agents directed against PS on tumor vasculature potentially could have utility for cancer treatment in man.

Acknowledgment

We thank Ms. Samia Burns for her help in preparing this manuscript.

REFERENCES

1. Williamson, P. and Schlegel, R.A., Back and forth: the regulation and function of transbilayer phospholipid movement in eukaryotic cells. *Molec.Mem.Biol.* 11, 199-216, 1994.
2. Zwaal, R.F. and Schroit, A.J., Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. *Blood* 89(4), 1121-1132, 1997.
3. Devaux, P.F., Protein involvement in transmembrane lipid asymmetry. *Annu Rev Biophys Biomol Struct* 21, 417-439, 1992.
4. Mouro, I., Halleck, M.S., Schlegel, R.A., Mattei, M., Williamson, P., Zachowski, A., Devaux, P., Cartron, J.P., and Colin, Y., Cloning, expression, and chromosomal mapping of a human ATPase II gene, member of the third subfamily of P-type ATPases and orthologous to the presumed bovine and murine aminophospholipid translocase. *Biochem.Biophys.Res Commun.* 257(2), 333-339, 1999.
5. Seigneuret, M. and Devaux, P.F., ATP-dependent asymmetric distribution of spin-labeled phospholipids in the erythrocyte membrane: relation to shape changes. *Proc Natl.Acad.Sci.USA* 81(12), 3751-3755, 1984.
6. Comfurius, P., Senden, J.M., Tilly, R.H., Schroit, A.J., Bevers, E.M., and Zwaal, R.F., Loss of membrane phospholipid asymmetry in platelets and red cells may be associated with calcium-induced shedding of plasma membrane and inhibition of aminophospholipid translocase. *Biochim.Biophys.Acta* 1026(2), 153-160, 1990.
7. Bitbol, M., Fellmann, P., Zachowski, A., and Devaux, P.F., Ion regulation of phosphatidylserine and phosphatidylethanolamine outside-inside translocation in human erythrocytes. *Biochim.Biophys.Acta* 904(2), 268-282, 1987.
8. Zhou, Q., Zhao, J., Stout, J.G., Luhm, R.A., Wiedmer, T., and Sims, P.J., Molecular cloning of human plasma membrane phospholipid scramblase. A protein mediating transbilayer movement of plasma membrane phospholipids. *J.Biol.Chem.* 272, 18240-18244, 1997.
9. Zhao, J., Zhou, Q., Wiedmer, T., and Sims, P.J., Level of expression of phospholipid scramblase regulates induced movement of phosphatidylserine to the cell surface. *J.Biol.Chem.* 273, 6603-6606, 1998.
10. Blankenberg, F.G., Katsikis, P.D., Tait, J.F., Davis, R.E., Naumovski, L., Ohtsuki, K., Kopiwada, S., Abrams, M.J., Darkes, M., Robbins, R.C., Maecker, H.T., and Strauss, H.W., In vivo detection and imaging of phosphatidylserine expression during programmed cell death. *Proc Natl.Acad.Sci.USA* 95(11), 6349-6354, 1998.
11. Bombeli, T., Karsan, A., Tait, J.F., and Harlan, J.M., Apoptotic vascular endothelial cells become procoagulant. *Blood* 89, 2429-2442, 1997.

12. Herrmann, A. and Devaux, P.F., Alteration of the aminophospholipid translocase activity during in vivo and artificial aging of human erythrocytes. *Biochim.Biophys.Acta* 1027(1), 41-46, 1990.
13. Sessions, A. and Horwitz, A.F., Myoblast aminophospholipid asymmetry differs from that of fibroblasts. *FEBS Lett.* 134(1), 75-78, 1981.
14. Adler, R., Ng, A.-K., and Rote, N.S., Monoclonal antiphosphatidylserine antibody inhibits intercellular fusion of the choriocarcinoma line, JAR. *Biol.Reprod.* 53(4), 905-910, 1995.
15. Vogt, E., Ng, A.-K., and Rote, N.S., A model for the antiphospholipid antibody syndrome: monoclonal antiphosphatidylserine antibody induces intrauterine growth restriction in mice. *Am J Obstet Gynecol* 174(2), 700-707, 1996.
16. Balch, C. and Dedman, J.R., Annexins II and V inhibit cell migration. *Exp Cell Res* 237(2), 259-263, 1997.
17. Rote, N.S., Ng, A.-K., Dostal-Johnson, D.A., Nicholson, S.L., and Siekman, R., Immunologic detection of phosphatidylserine externalization during thrombin-induced platelet activation. *Clin.Immunol.Immunopathol.* 66, 193-200, 1993.
18. Zwaal, R.F., Bevers, E.M., Comfurius, P., Rosing, J., Tilly, R.H., and Verhallen, P.F., Loss of membrane phospholipid asymmetry during activation of blood platelets and sickled red cells; mechanisms and physiological significance. *Mol Cell Biochem* 91(1-2), 23-31, 1989.
19. Sims, P.J., Faioni, E.M., Wiedmer, T., and Shattil, S.J., Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. *J Biol.Chem* 263(34), 18205-18212, 1988.
20. Demo, S.D., Masuda, E., Rossi, A.B., Thromsdet, B.T., Gerard, A.L., Chan, E.H., Armstrong, R.J., Fox, B.P., Lorens, J.B., Payan, D.G., Scheller, R.H., and Fisher, J.M., Quantitative measurement of mast cell degranulation using a novel flow cytometric annexin-V binding assay. *Cytometry* 36(4), 340-348, 1999.
21. Qu, J., Conroy, L.A., Walker, J.H., Wooding, F.B., and Lucy, J.A., Phosphatidylserine-mediated adhesion of T-cells to endothelial cells. *Biochem J* 317(pt. 2), 343-346, 1996.
22. Lupu, F., Moldovan, N., Ryan, J., Stern, D., and Simionescu, N., Intrinsic procoagulant surface induced by hypercholesterolaemia on rabbit aortic endothelium. *Blood Coagul Fibrinolysis* 4(5), 743-752, 1993.
23. van Geelen, A.G., Slobbe-van Drunen, M.E., Muller, A.D., Bruggeman, C.A., and Van Dam-Mieras, M.C., Membrane related effects in endothelial cells induced by human cytomegalovirus. *Arch Virol* 140(9), 1601-1612, 1995.

24. Christiansen, V.J., Sims, P.J., and Hamilton, K.K., Complement C5b-9 increases plasminogen binding and activation on human endothelial cells. *Arterioscler Thromb Vasc Biol* 17(1), 164-171, 1997.
25. Julien, M., Millot, C., Tocanne, J.F., and Tournier, J.F., 12-O-tetradecanoylphorbol-13-acetate uinhbits aminophospholipid translocase activity and modifies the lateral motions of fluorescent phospholipid analogs in the plasma membrane of bovine aortic endothelial cells. *Exp Cell Res* 234(1), 125-131, 1997.
26. Cichorek, M., Kozłowska, K., Witkowski, J.M., and Zarzeczna, M., Flow cytometric estimation of the plasma membrane diversity of transplantable melanomas, using annexin V. *Folia Histochem.Cytobiol.* 38(1), 41-43, 2000.
27. Utsugi, T., Schroit, A.J., Connor, J., Bucana, C.D., and Fidler, I.J., Elcvated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. *Cancer Res* 51(11), 3062-3066, 1991.
28. Sugimura, M., Donato, R., Kakkar, V.V., and Scully, M.F., Annexin V as a probe of the contribution of anionic phospholipids to the procoagulant activity of tumour cell surfaces. *Blood Coagul Fibrinolysis* 5(3), 365-373, 1994.
29. McEvoy, L., Williamson, P., and Schlegel, R.A., Membrane phospholipid asymmetry as a determinant of erythrocyte recognition by macrophages. *Proc Natl.Acad.Sci.USA* 83(10) , 3311-3315, 1986.
30. Tait, J.F. and Smith, C., Phosphatidylserine rccptors: role of CD36 in binding of anionic phospholipid vesicles to monocytic cells. *J Biol.Chem* 274(5), 3048-3054, 1999.
31. Test, S.T. and Mitsuyoshi, J., Activation of the alternative pathway of complement by calcium-loaded erythrocytes resulting from loss of membrane phospholipid asymmetry. *J Lab Clin Med* 130(2), 169-182, 1997.
32. Bevers, E.M., Rosing, J., and Zwaal, R.F., Development of procoagulant binding sites on the platelet surface. *Adv.Exp.Med.Biol.* 192, 359-371, 1985.
33. Dachary-Prigent, J., Toti, F., Satta, N., Pasquet, J.M., Uzan, A., and Freyssinet, J.M., Physiopathological significance of catalytic phospholipids in the generation of thrombin. *Seminars.In Thrombosis.&.Hemostasis.* 22, 157-164, 1996.
34. Aguilar, L., Ortega-Pierres, G., Campos, B., Fonesca, R., Ibanez, M., Wong, C., Farfan, N., Naciff, J.M., Kaetzel, M.A., and Dedman, J.R., Phospholipid membranes form specific nonbilayer molecular arrangements that are antigenic. *J Biol.Chem* 274(36), 25193-25196, 1999.
35. Tait, J.F., Cerqueira, M.D., Dewhurst, T.A., Fujikawa, K., Ritchie, J.L., and Stratton, J.R., Evaluation of annexin V as a platelet-directed thrombus targeting agent. *Thromb.Res.* 75, 491-501, 1994.

36. Huang, X., Molema, G., King, S., Watkins, L., Edgington, T.S., and Thorpe, P.E., Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. *Science* 275, 547-550, 1997.
37. Ran, S., Gao, B., Duffy, S., Watkins, L., Rote, N.S., and Thorpe, P.E., Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. *Cancer Res* 58(20), 4646-4653, 1998.
38. Nilsson, F., Kosmehl, H., Zardi, L., and Neri, D., Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. *Cancer Res* 61(2), 711-716, 2001.
39. Leppink, D.M., Bishop, D.K., Sedmak, D.D., Henry, M.L., Ferguson, R.M., Streeter, P.R., Butcher, E.C., and Orosz, C.G., Inducible expression of an endothelial cell antigen on murine myocardial vasculature in association with interstitial cellular infiltration. *Transplantation* 48(5), 874-877, 1989.
40. Burrows, F.J., Watanabe, Y., and Thorpe, P.E., A murine model for antibody-directed targeting of vascular endothelial cells in solid tumors. *Cancer Res.* 52, 5954-5962, 1992.
41. Fries, J.W.U., Williams, A.J., Atkins, R.C., Newman, W., Lipscomb, M.F., and Collins, T., Expression of VCAM-1 and E-selectin in an in vivo model of endothelial activation. *Am.J.Pathol.* 143, 725-737, 1993.
42. Krajewska, M., Wang, H.G., Krajewski, S., Zapata, J.M., and Shabaik, A., Immunohistochemical analysis of in vivo patterns of expression of CPP32 (Caspase-3), a cell death protease. *Cancer Res* 57(8), 1605-1613, 1997.
43. Gavrieli, Y., Sherman, Y., and Ben-Sasson, S.A., Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. *J Cell Biol.* 119(3), 493-501, 1992.
44. Shepro, D. and Morel, N.M., Pericyte physiology. *FASEB J* 7(11), 1031-1038, 1993.
45. Benjamin, L.E., Golijanin, D., Itin, A., Pode, D., and Keshet, E., Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. *J Clin Invest.* 103(2), 159-165, 1999.
46. Bocci, V., Efficient labeling of serum proteins with ¹³¹I using chloramine T. *Int.J.Appl.Radiat.Isot.* 15, 449-456, 1964.
47. Bradford, M.M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal.Biochem.* 72, 248-254, 1976.
48. Lucas, R., Garcia, I., Donati, Y.R., Hribar, M., Mandriota, S.J., Giroud, C., Buurman, W.A., Fransen, L., Suter, P.M., Nunez, G., Pepper, M.S., and Grau, G.E., Both TNF receptors are required for direct TNF-mediated cytotoxicity in microvascular endothelial cells. *Eur J Immunol* 28(11), 3577-3586, 1998.

49. Daum, G., Lipids of mitochondria. *Biochim.Biophys.Acta* 822(1), 1-42, 1985.
50. Lichtenbeld, H.H., Van Dam-Mieras, M.C., and Hillen, H.F., Tumour angiogenesis: pathophysiology and clinical significance. *Neth J Med* 49(1), 42-51, 1996.
51. Harris, A.L., Zhang, H., Moghaddam, A., Fox, S., Scott, P., Pattison, A., Gatter, K., Stratford, I., and Bicknell, R., Breast cancer angiogenesis--new approaches to therapy via antiangiogenesis, hypoxic activated drugs, and vascular targeting. *Breast Cancer Res.Treat.* 38(1), 97-108, 1996.
52. Ralcigh, J.A., Dewhirst, M.W., and Thrall, D.E., Measuring Tumor Hypoxia. *Semin Radiat Oncol* 6(1), 37-45, 1996.
53. Toyokuni, S., Okamoto, K., Yodoi, J., and Hiai, H., Persistent oxidative stress in cancer. *FEBS Lett.* 358(1), 1-3, 1995.
54. Kraus, M. and Wolf, B., Implications of acidic tumor microenvironment for neoplastic growth and cancer treatment: a computer analysis. *Tumour.Biology.* 17(3), 133-154, 1996.
55. Rao, L.V.M., Tait, J.F., and Hoang, A.D., Binding of annexin V to a human ovarian carcinoma cell lines (OC-2008). Contrasting effects on cell surface factor VIIa/tissue factor activity and prothrombinase activity. *Thromb.Res.* 67, 517-531, 1992.
56. Hammill, A.K., Uhr, J.W., and Scheuermann, R.H., Annexin V staining due to loss of membrane asymmetry can be reversible and precede commitment to apoptotic death. *Exp Cell Res* 251(1), 16-21, 1999.
57. Dillon, S.R., Mancini, M., Rosen, A., and Schlissel, M.S., Annexin V binds to viable B cells and colocalizes with a marker of lipid rafts upon B cell receptor activation. *J Immunol* 164(3), 1322-1332, 2000.
58. Holland, J.A., Meyer, J.W., Chang, M.M., O'Donnel, R.W., Johnson, D.K., and Ziegler, L.M., Thombin stimulated reactive oxygen species production in cultured human endothelial cells. *Endothelium* 6(2), 113-121, 1998.
59. Zulueta, J.J., Yu, F.S., Hertig, I.A., Thannickal, V.J., and Hassoun, P.M., Release of hydrogen peroxide in response to hypoxia-reoxygenation: role of an NAD(P)H oxidase-like enzyme in endothelial cell plasma membrane. *Am J Respir Cell Mol Biol* 12(1), 41-49, 1995.
60. Vogt, E., Ng, A.-K., and Rote, N.S., Antiphosphatidylserine antibody removes annexin-V and facilitates the binding of prothrombin at the surface of a choriocarcinoma model of trophoblast differentiation. *Am J Obstet Gynecol* 177(4), 964-972, 1997.
61. Ferro, D., Pittoni, V., Quintarelli, C., Basili, S., Saliola, M., Caroselli, C., Valesini, G., and Violi, F., Coexistence of anti-phospholipid antibodies and endothelial perturbation in systemic lupus erythematosus patients with ongoing prothrombotic state. *Circulation* 95(6), 1425-1432, 1997.

62. Nakamura, N., Shidara, Y., Kawaguchi, N., Azuma, C., Mitsuda, N., Onishi, S., Yamaji, K., and Wada, Y., Lupus anticoagulant autoantibody induces apoptosis in umbilical vein endothelial cells: involvement of annexin V. *Biochem Biophys Res Commun* 205(2), 1488-1493, 1994.

Table 1 Specific localization of anti-PS and anti-CL antibodies to tumor vessels mice

Tissue	Anti-PS^a	Anti-cardiolipin
L540 tumor	++ ^b	-
H358 tumor	++	-
HT29 tumor	+	-
B16 tumor	+++	-
3LL tumor	++	-
Colo 26 tumor	++	-
Adrenal	-	-
Brain	-	-
Heart	-	-
Kidney	- ^c	- ^c
Intestine	-	-
Liver	-	-
Lung	-	-
Pancreas	-	-
Spleen	-	-
Testis	-	-

^a Localization of anti-PS or anti-CL antibody in tumor bearing mice was determined by injecting the antibody, perfusing the blood circulation of the mice with saline and detecting the antibody on sections of the tissues by using an anti-mouse IgM - peroxidase conjugate.

^b Intensity of staining was compared to pan-endothelial marker MECA 32; - indicates no staining; + weak (fewer than 5% positive vessels) ; ++ moderate (5 to 20 %); +++ (20 to 40 %) strong.

^c Non-antigen specific tubular staining was visible in both anti-PS and anti-CL recipients.

Table 2 Expression of apoptotic markers in tumors

Tumor type	Active caspase-3		Tunel assay	
	Tumor cells (% of total) ^a	Tumor vessels	Tumor cells (% of total)	Tumor vessels
3LL	19.8	<1.0 ^b	12.6	0
HT29	13.7	0	7.8	0
H358	5.8	0	4.3	0
Colo 26	5.3	0	4.1	0
B16	4.2	0	3.5	0
L540	2.3	0	1.6	0

^a The percentage of tumor cells or tumor blood vessels that were positive for either caspase-3 or Tunel was determined in ten high power fields per section. The fields were randomly selected along two perpendicular directions from the edges through the center of the tumor. The average of the percentage of positive cells or vessels in tumor from 3 mice is presented.

^b Occasional vessels (1 of >100) in the necrotic area of 3LL tumor displayed both markers of apoptosis.

Table 3 Effect of cytokines, growth factors and stress conditions on exposure of PS on endothelial cells *in vitro*.

Treatment	Concentration ^a	¹²⁵ I-Annexin V (% of Max binding) ^b	
		ABAE cells	bEnd.3 cells
Medium with 10% serum	N/A ^c	0	0
Actinomycin D + TNF α	50 ng/ml each	100	100
VEGF	20 ng/ml	0	0
β FGF	20 ng/ml	0	0
Scatter factor	40 ng/ml	0	0
TGF β_1	20 ng/ml	0	0
PDGF-BB	20 ng/ml	0	0
IL-10	20 ng/ml	0	0
IL-8	20 ng/ml	0	0
IL-6	20 ng/ml	0	0
IL-1 α	10 ng/ml	6.4	7.5
IL-1 β	10 ng/ml	5.8	5.5
Interferon	40 ng/ml	8.6	2.8
TNF α	20 ng/ml	7.4	13.7
Thrombin	50 nM	8.8	17.4
Hypoxia	1% O ₂	15.0	22.5
pH 6.6 ^d	N/A	20.2	18.9
Hydrogen peroxide	100 μ M ^e	95.5	98.4

^a Concentrations of cytokines, growth factors and thrombin were selected from literature values to have maximal stimulatory effect on cultured endothelial cells. These concentrations did not cause toxicity over the period of the test (24 hours) as judged by morphological appearance, a lack of detachment, and a lack of uptake of trypan blue.

^b Binding of ¹²⁵I-annexin V was performed as described under Methods. Basal binding was determined in the presence of growth medium alone. Maximal PS exposure was determined after induction of apoptosis by the combined treatment with actinomycin D and TNF α . Untreated ABAE and bEnd.3 cells bound 0.44 and 0.68 pmoles of ¹²⁵I-Annexin V, respectively. Maximal binding was 6.2 pmoles of ¹²⁵I-annexin V for both cell types (equivalent to 3.8×10^6 molecules per cell). The percentage of increase of annexin V binding was calculated according to the following formula: (net experimental binding / net maximal binding) X 100. Average of duplicates from three separate experiments is presented. SE was less than 5%.

^c Not applicable.

^d Cells were exposed to the growth medium lacking bicarbonate that had been adjusted to pH 6.6 with 1N HCl. Cells were incubated at 37°C in the absence of CO₂.

^e The maximal concentration of H₂O₂ that did not cause cytotoxicity under chosen conditions.

Figure Legends:

Fig. 1. Localization of anti-PS antibody to vascular endothelial cells in L540 human Hodgkin's lymphoma, 3LL murine lung carcinoma and B16 murine melanoma tumors in mice. Tumor-bearing SCID mice were injected intravenously with 20 ug of anti-PS or anti-CL mouse IgM. The blood circulation was perfused with saline one hour later. Mice were sacrificed one hour later and tumor and organs were harvested and snap-frozen. Mouse IgM was detected on frozen sections using goat anti-mouse IgM-peroxidase conjugate. Anti-PS antibody specifically localized to blood vessels (indicated by arrows) in all tumors. No localization was observed in mice injected with control anti-CL IgM.


Fig. 2. Lack of apoptotic vascular endothelial cells in 3LL and L540 tumors. Frozen sections of 3LL and L540 tumors were double labeled with a pan-endothelial cell antibody, MECA 32 to visualize blood vessels, and with anti-apoptotic markers detecting either active caspase-3 or fragmented DNA (Tunel assay). MECA 32 staining of vessels is indicated by the brown color (arrows). Expression of apoptotic markers is indicated by the pink color (arrowheads). Both apoptotic markers are present in some tumor cells but are absent from tumor endothelium.

Fig 3. Pericyte-endothelial cell interactions in PS-positive and PS-negative vessels in 3LL tumors. Mice bearing 3LL tumors were injected with 20 ug of anti-PS IgM. PS-positive vessels (*upper panel*) were detected as described above. PS-negative vessels (defined as MECA 32-positive, anti-PS-negative) were identified on serial sections of the same tumor (*lower panel*). Vessels were labeled brown with the pan-endothelial cell marker. Pericytes were identified with anti- α SMC actin antibody and were stained pink (arrowheads). Representative fields of PS-positive, pericyte-negative (*upper left*), PS-positive, pericyte-positive (*upper right*), PS-negative, pericyte-negative (*lower left*) and PS-negative, pericyte-positive (*lower right*) vessels are shown. Note the detachment of the pericytic layer from tumor endothelium and the uneven distribution of pericytes along tumor vessels (*upper and lower right*).

Fig. 4. Externalized PS on bEnd.3 mouse endothelial cells treated with 100 uM of hydrogen peroxide. A) untreated bEnd.3 cells; B) bEnd.3 cells after treatment with 100 uM of hydrogen peroxide. PS is absent from the surface of untreated cells but becomes externalized after treating the cells with H_2O_2 . PS-positive cells remain attached to the substratum, retain cell-cell contact and other morphological signs of viability.

Fig. 5. Synergistic effect of hypoxia and inflammatory cytokines on PS exposure. bEnd.3 cells were treated for 24 hours with IL-1 α and TNF α under normoxic and hypoxic conditions. PS externalization was determined on viable endothelial monolayer by measuring binding of ^{125}I -annexin V. The increase in PS exposure was calculated as explained under "Materials and Methods".

Fig. 6. Hypothesis for induction of PS exposure on tumor vessels and its contribution to the procoagulant shift of the tumor endothelium.

CERTIFICATE OF EXPRESS MAILING	
NUMBER	EL 522 496 735 US
DATE OF DEPOSIT	November 30, 2001
I hereby certify that this paper or fee is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service on the date indicated above and is addressed to: U.S. Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202.	
 Pam Mitchell	

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Philip E. Thorpe and Sophia Ran

Serial No.: Unknown

Filed: Concurrently Herewith

For: COMBINED CANCER TREATMENT
METHODS USING ANTIBODIES TO
AMINOPHOSPHOLIPIDS

Group Art Unit: 1642

Examiner: G. Bansal

Atty. Dkt. No.: 4001.002299

SUBMISSION OF FORMAL DRAWINGS

ATTN OFFICIAL DRAFTSMAN
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicants hereby submit the formal drawings for the above-referenced application
(Figures 1A through 4B on 3 sheets) and request that these drawings be accepted for filing.

Respectfully submitted,



Shelley P.M. Fussey
Reg. No. 39,458

Agent for Applicants

WILLIAMS, MORGAN & AMERSON
7676 Hillmont, Suite 250
Houston, Texas 77040
(713) 934-7000
Date: November 30, 2001

FIG. 1A

FIG. 1B

FIG. 4A




FIG. 4A




FIG. 4B